Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    Elsamitrucin
Show Display Options
Rank Status Study
1 Completed Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Mantle Cell Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Intervention: Drug: Elsamitrucin
2 Completed Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Elsamitrusin

Indicates status has not been verified in more than two years